Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-03
2007-07-03
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S320100, C435S455000, C435S458000, C536S023100, C536S024500
Reexamination Certificate
active
09962489
ABSTRACT:
A method for the direct in vivo transformation of cells in and surrounding a solid tumor is disclosed. This method is based on the site-specific delivery of proteins to solid tumors and to tissue surrounding the solid tumor by direct injection of a nucleic acid sequence. In particular, this method is directed to site-specific delivery of nucleic acids encoding major histocompatibility proteins, cytokines, and toxins to a solid tumor. This technique provides for the transfer of vectors and expression of recombinant genes in vivo and allows the introduction of proteins of therapeutic or diagnostic value for the treatment of disease.
REFERENCES:
patent: 4182330 (1980-01-01), Michaels
patent: 4332893 (1982-06-01), Rosenberg
patent: 4351337 (1982-09-01), Sidman
patent: 4353888 (1982-10-01), Sefton
patent: 4636195 (1987-01-01), Wolinsky
patent: 4714460 (1987-12-01), Calderon
patent: 4824436 (1989-04-01), Wolinsky
patent: 4857054 (1989-08-01), Helfer
patent: 4874746 (1989-10-01), Antoniades et al.
patent: 5049132 (1991-09-01), Shaffer et al.
patent: 5082670 (1992-01-01), Gage et al.
patent: 5087617 (1992-02-01), Smith
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5662896 (1997-09-01), Barber et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5707969 (1998-01-01), Nabel et al.
patent: 5762926 (1998-06-01), Gage et al.
patent: 5846225 (1998-12-01), Rosengart et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5997859 (1999-12-01), Barber et al.
patent: 6096722 (2000-08-01), Bennett et al.
patent: 6203991 (2001-03-01), Nabel et al.
patent: 6410322 (2002-06-01), Robinson
patent: 0 273 085 (1986-12-01), None
patent: 0206939 (1986-12-01), None
patent: 0 882 791 (1998-12-01), None
patent: 0 882 792 (1998-12-01), None
patent: 0 889 126 (1999-01-01), None
patent: 0 889 126 (1999-01-01), None
patent: 0 882 792 (1999-06-01), None
patent: 0 889 126 (1999-09-01), None
patent: 0 882 791 (2000-01-01), None
patent: 61092572 (1986-05-01), None
patent: 62181799 (1987-08-01), None
patent: 63022024 (1988-01-01), None
patent: WO83/01894 (1983-06-01), None
patent: 83/03356 (1983-10-01), None
patent: WO83/03356 (1983-10-01), None
patent: WO88/9378 (1988-01-01), None
patent: WO89/198 (1989-01-01), None
patent: WO89/2468 (1989-05-01), None
patent: WO90/02580 (1990-03-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 90/11734 (1990-10-01), None
patent: WO 91/06309 (1991-05-01), None
patent: WO 94/27612 (1994-12-01), None
patent: WO 95/12979 (1995-05-01), None
patent: WO 96/20276 (1996-07-01), None
patent: WO 96/20731 (1996-07-01), None
patent: WO 96/39830 (1996-12-01), None
patent: WO 97/14307 (1997-04-01), None
patent: WO 97/26337 (1997-07-01), None
patent: WO 98/10071 (1998-03-01), None
patent: WO 98/32859 (1998-07-01), None
Peracchi, A. et al., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2000).
Chirila, T. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Branch, A. Trends in Biochem. Sci. TIBS), vol. 23, pp. 45-60 (1998).
Crooke. S. Antisense Research and Application, Chapters 1 and 2, pp. 1-50, Ed. by S. Crooke, Publ. Springer-Verlag (1998).
Mulligan, Richard C., The Basic Science of Gene Therapy, Science, vol. 260, May 14, 1993.
Hiroshi, Arai et al., Gene transfer of Fas ligand induces tumor regression in vivo, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 13862-13867, Dec. 1997.
Hiroshi, Arai et la., Inhibition of the alloantibody response by CD95 ligand, Nature Medicine, vol. 3, No. 8, Aug. 1997.
Brown, David, Gene Therapy ‘Oversold’ By Researchers, Journalists, The Washington Post, Dec. 8, 1995.
Bubenik, J. et al., Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu
u mice, Immunology Letters, 19 (1988) 279-282.
Coghlan, Andy, Gene dream fades away, New Scientist, Nov. 25, 1995.
Felgner, Philip L. et al., Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci, USA, vol. 84, pp. 7413-7417, Nov. 1987.
Nabel, Elizabeth G. et al., Recombinant Gene Expression in Vivo Within Endothelial Cells of the Arterial Wall, Science, pp. 1342-1344, vol. 244.
Nabel, Gary J. et al., Immunotherapy for Cancer by Direct Gene Therapy into Tumors, Human Gene Therapy, 5:57-77 (1994), Mary Ann Liebert, Inc., Publishers.
Nabel, Elizabeth G. et al., Site-Specific Gene Expression in Vivo by Direct Gene Transfer Into the Arterial Wall, Science, pp. 1285-1288, vol. 249, Sep. 1990.
Nabel, Gary J. et al., Immune response in human melanoma after transfer of an allogeneic class I major histocompatiblity complex gene with DNA-liposome complexes, Proc. Nal. Acad. Sci. USA, vol. 93, p. 15388-15393, Dec. 1996.
Nabel, Gary, J. et al., Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 11307-11311, Dec. 1993.
Nabel, Gary J., Response to the Points to Consider for Immunotherapy of Malignancy by In Vivo Gene Transfer into Tumors, Human Gene Therapy, 3:705-711 (1992), Mary Ann Liebert, Inc., Publishers.
Ogura, Hiromi et al, Implantation of Genetically Manipulated Fibroblasts into Mice as Antitumor α-Interferon Therapy, Cancer Research 50, 5102-5106, Aug. 15, 1990.
Plautz, Gregory E. et al., Immunotherapy of malignancy by in vivo gene transfer into tumors, Proc. Natl. Acad. Sci. USA, vol. 90 4645-4649, May 1993.
Selden, Richard F. et al., Implantation of Genetically Engineered Fibroblasts into Mice: Implications for Gene Therapy, Science, vol. 236, pp. 714-718, May 1987.
Tanaka, Kenichi et la., Reversal of Oncogenesis by the Expression of a Major Histocompatibility Complex Class 1 Gene, Science, vol. 228, pp. 26-30, Apr. 1985.
Wang, Chen-Yen et al., Highly Efficient DNA Delivery Mediated by pH-Sensitive Immunoliposomes, Biochemistry 1989, 28, 9508-9514.
Wilson, James M. et al., Implantation of Vascular Grafts lined with Genetically Modified Endothelial Cells, Science, vol. 244, pp. 1344-1346, Jun. 1989.
Wolff, Jon A. et al, Transfer into Mouse Muscle In Vivo, Science, vol. 247, Mar. 1990.
Zwiebel, James A. et al., High-Level Recombinant Gene Expression in Rabbit Endothelial Cells Transduced by Retroviral Vectors, Science, vol. 243, pp. 220-222 , Jan. 1989.
Broadley et al., Transfection of wounds in vivo with Transforming Growth Factor-β1Accelerates Healing, Federation of American Societies for Experimental Biology Journal, vol. 5, No. 4, pp. 539A, abstract 977, 1991.
Kass-Eisler, Alyson, “Plasmid DNA and Recombinant Adenoviruses as Vectors for Foreign Gene Transfer to the Heart”, Dissertation Abstracts Online, available in DIALOG, File No. 35.
Adis R&D Insight, “Fibroblast growth factor-2”, available in DIALOG, File No. 107.
Adis R&D Insight, “Adenyl cyclase gene therapy-Collateral Therapeutics”, available in DIALOG, File No. 107.
Pharmaprojects, “Fibroblast Growth Factor”, available in Dialog, File No. 128.
Pharmaprojects, “AAV Vectors, Somatix”, available in Dialog, File No. 128.
“Gene Therapy for Myocardial Infarction by In Vivo Transfer of Human Hepatocyte Growth Factor (HGF)”, J. Japanese College Angiology 39(5):213-218 (1999) (Abstract only).
Chao et al., “Gene Therapy for Hypertension-A Review of Potential Targets”, BioDrugs 11(1):43-53 (1999).
Partridge, T.A., “Muscle Transfection Made Easy”, Nature 352(6338):757-758 (1991).
Lewis et al., “Angiogenesis By Gene Therapy: A New Horizon for Myocardial Vascularization?”, Cardiovascular Research, 35(3): 490-497 (1997).
Blau, H.M. and Dhawan, J., “Systemic delivery of recombinant proteins by genetically engineered myoblasts”, J. Cell. Biochem. Suppl. 18A, 188 (1994).
Leiden, J.M.; Parmacek, M.S.; Bolling, S.; et al. “Expression of Heterologous Genes Following Direct Injection into Myocardium Suggests a Novel App
Nabel Elizabeth G.
Nabel Gary J.
Brinks Hofer Gilson & Lione
The Regents of the University of Michigan
Zara Jane
LandOfFree
Treatment of diseases by site-specific instillation of cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diseases by site-specific instillation of cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diseases by site-specific instillation of cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3750680